Immunovant IMVT
NASDAQ IMVT
$28.36 -0.23 (-0.79%)
As of: Oct 21, 2026 · 3:59 PM EDT

Immunovant (IMVT) Debt Ratio (2018 - 2019)

Updated

Immunovant's (IMVT) Debt Ratio stood at 0.02 in fiscal Q4 2019 (quarter ended Mar 31, 2019), down 97.1% from the prior quarter.

Analysis

Immunovant (IMVT) Debt Ratio (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 0.39
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 0.24
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 0.52
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 0.42
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 0.08
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 0.28
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 0.60
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 0.53
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 0.31
10 Immunovant 5.85 Bn 2.63 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 0.02
Dec 31, 2018 0.74
API Access

Immunovant Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=IMVT&period=max&api_key=YOUR_API_KEY